Spero Therapeutics, Inc (SPRO) insider trading

Every open-market stock purchase and sale by Spero Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.

Insider activity at a glance

  • Insiders sold $552K over the last 12 months (6 sales). No open-market buys.
  • Last insider buy: Aquilo Capital Management LLC (10% owner), $208K, 4 years ago.

Last 12 months: insiders bought $0 (0 buys) and sold $552K (6 sales). Last close $1.26 on Aug 7, 2026.

Recent SPRO insider trades

DateInsiderTradeValue
Aug 3, 2026Debra Zack (C-suite exec)Bought (not open market)—
Aug 3, 2026Debra Zack (C-suite exec)Bought (not open market)—
Jun 23, 2026Cynthia Smith (Insider)Bought (not open market)—
Jun 23, 2026Cynthia Smith (Insider)Bought (not open market)—
Jun 23, 2026Milind Deshpande (Insider)Bought (not open market)—
Jun 23, 2026Milind Deshpande (Insider)Bought (not open market)—
Jun 23, 2026Scott Thomas Jackson (Insider)Bought (not open market)—
Jun 23, 2026Scott Thomas Jackson (Insider)Bought (not open market)—
Jun 23, 2026John C Pottage Jr (Insider)Bought (not open market)—
Jun 23, 2026Kathleen Tregoning (Insider)Bought (not open market)—
Jun 23, 2026Kathleen Tregoning (Insider)Bought (not open market)—
Jun 23, 2026Patrick V.j.j. Vink (Insider)Bought (not open market)—
Jun 23, 2026Patrick V.j.j. Vink (Insider)Bought (not open market)—
Jun 23, 2026Frank E Thomas (Insider)Bought (not open market)—
Jun 23, 2026Frank E Thomas (Insider)Bought (not open market)—
Jun 23, 2026John C Pottage Jr (Insider)Bought (not open market)—
May 4, 2026Esther Rajavelu (Insider)Sold$63.4K
Feb 6, 2026Esther Rajavelu (Insider)Sold$120K
Feb 6, 2026Esther Rajavelu (Insider)Sold$87.6K
Feb 6, 2026Timothy Keutzer (COO)Sold$44K
Feb 4, 2026Timothy Keutzer (COO)Sold$7.8K
Feb 3, 2026Timothy Keutzer (COO)Sold$51.8K
Feb 2, 2026Timothy Keutzer (COO)Sold$41.6K
Feb 2, 2026Esther Rajavelu (Insider)Sold$40.6K
Feb 2, 2026Esther Rajavelu (Insider)Bought (not open market)—

Who's trading SPRO

Get free alerts when an insider at Spero Therapeutics, Inc files a new trade →